New MRI-Guided radiation aims to hit lung tumors without harming nearby organs
NCT ID NCT04925583
First seen Mar 10, 2026 · Last updated Jun 22, 2026 · Updated 14 times
Summary
This phase 1 trial tests a precise radiation technique for lung tumors located very close to the windpipe or food pipe. Using daily MRI scans and real-time adjustments, doctors hope to deliver higher radiation doses safely. Up to 38 adults with ultracentral lung tumors will receive one of four dose levels to find the safest maximum dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Hospital of Heidelberg, Radiation Oncology
Heidelberg, 69120, Germany
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Magnetic resonance guided adaptive stereotactic body radiotherapy (SBRT)
What this could lead to
If successful, this could establish a safer way to deliver high-dose radiation to hard-to-treat lung tumors near the airways and esophagus.
What could go wrong
This is an early phase 1 trial with only 38 participants, focused on safety and dosing. It may not lead to a standard treatment, and there are risks of lung, esophageal, or heart side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.